Wire · opportunities
Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 September 2026 · Fusion42 review
Antengene has dosed the first patient in China for the pivotal Phase III CLINCH-3 trial of ATG-022, a targeted therapy for advanced gastric and gastroesophageal junction adenocarcinoma, aiming for regulatory approval supported by breakthrough therapy designation by China's NMPA. The trial will expand into a multi-regional study with the goal of establishing ATG-022 as a monotherapy for CLDN18.2 positive cancers.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You can target the Chinese gastric cancer market now with a path cleared by the NMPA's breakthrough designation for Antengene’s ATG-022. Clinical data supports a near-term opportunity to establish your therapy for CLDN18.2+ tumors in this underserved segment.
◆ Coverage
2 sources · 21 Sep 2026
◆ Related on Wire
◆ Topics